• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Insulet inks 5-year, $100 million, 11-nation OmniPod distribution deal

UPDATE: Insulet inks 5-year, $100 million, 11-nation OmniPod distribution deal

January 5, 2010 By MassDevice staff

The OmniPod is going global.

Bedford, Mass.-based Insulet Corp. (NSDQ:PODD) signed a five-year, $100 million international distribution deal with Ypsomed AG (SIX:YPSN) to exclusively distribute the insulin management system in 11 countries, including China.

Ypsomed, a Swiss distributor of insulin pumps, blood glucose meters and diabetes care supplies, has networks around the globe, according to a press release. The terms of the deal give Ypsomed the exclusive right to promote, advertise, market, distribute and sell Insulet‘s OmniPod, starting in Germany, France and the U.K. in June and then other parts of Europe and Australia shortly thereafter. In 2011, the company will begin marketing the Omnipod in China.

The deal also gives Ypsomed a right of first refusal on distribution rights in all other countries except the U.S., Canada and Israel, according to a securities filing. The Swiss firm must makes annual purchases totaling $100 million over the five-year term of the deal, weighted toward the end of the term. That means the agreement isn’t likely to have a material impact on Insulet’s books this year, according to the filing. Ypsomed also agreed not to manufacture, sell or distribut any other insulin infusion devices which adhere to a user’s skin; according to the filing, the companies are likely to co-brand the OmniPod slated for distribution by Ypsomed with the Swiss company’s MYLIFE diabetes care brand. And 15months before the deal expires, the companies plan to “negotiate in good faith to enter into an amendment to the Agreement which would include a renewal term. Upon termination or expiration of the Agreement, [Insulet] has agreed to pay certain termination/expiration fees. These fees would be based on sales of the [Insulet]’s products made during the twelve months following such termination or expiration to customers who had purchased the Company’s products from Ypsomed during the term of the Agreement,” according to the filing.

Insulet won CE Mark approval in April, 2009, for its flagship product. At the time, vice president of clinical research Rob Campbell told MassDevice that the company had “outgrown our manufacturing constraints in the U.S., which led us to look to outside markets.” The company was actively working to set up a distribution deal at the time, Campbell said.

Filed Under: Business/Financial News, News Well Tagged With: Endocrinology, Insulet, Insulin Management

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy